Grace Therapeutics (GRCE) Change in Receivables (2019 - 2025)
Grace Therapeutics' (GRCE) quarterly Change in Receivables came in at -$106000.0 in Q2 2025, up 67.48% year-over-year from -$63289.4 in Q2 2024, and up 39.43% quarter-over-quarter from -$175000.0 in Q1 2025.
Powered by 
Analysis
Grace Therapeutics (GRCE) Change in Receivables (2019 - 2025) Analysis & Trends
Grace Therapeutics has disclosed Change in Receivables across 6 years of filings, most recently posting -$106000.0 for Q2 2025.
- In Q2 2025, Change in Receivables rose 67.48% year-over-year to -$106000.0; the TTM figure through Mar 2026 stood at -$106000.0 (up 82.21% YoY), while the FY2026 annual figure was -$106000.0, up 82.21% from the prior year.
- Change in Receivables came in at -$106000.0 for Q2 2025 at Grace Therapeutics, up from -$175000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $380000.0 in Q3 2021 to a low of -$326000.0 in Q2 2024.
- Average Change in Receivables over 4 years is -$35250.0, with a median of -$37000.0 recorded in 2021.
- Year-over-year, Change in Receivables jumped 219.33% in 2021 and sank 1031.43% in 2024.
- Over 4 years, Change in Receivables stood at $380000.0 in 2021, then slumped by 67.89% to $122000.0 in 2023, then slumped by 193.44% to -$114000.0 in 2024, then grew by 7.02% to -$106000.0 in 2025.
- Per Business Quant data, the three most recent Change in Receivables figures were -$106000.0 in Q2 2025, -$175000.0 in Q1 2025, and -$114000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.01 Bn | 621.25 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 446.87 Bn | 440.30 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 358.09 Bn | 350.95 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.67 Bn | 259.98 Bn | 11.24 Bn | - |
| 5 | Pfizer | 156.85 Bn | 145.15 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.23 Bn | 44.85 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.11 Bn | 43.11 Bn | - | - |
| 8 | Incyte | 24.62 Bn | 20.08 Bn | 1.57 Bn | 73.80 Mn |
| 9 | United Therapeutics | 21.29 Bn | 18.62 Bn | 683.80 Mn | -1.70 Mn |
| 10 | Grace Therapeutics | 39.38 Mn | 39.38 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -106,000.00 |
| Mar 31, 2025 | -175,000.00 |
| Dec 31, 2024 | -114,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Jun 30, 2024 | -326,000.00 |
| Mar 31, 2024 | -237,000.00 |
| Dec 31, 2023 | 122,000.00 |
| Jun 30, 2023 | 35,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Sep 30, 2021 | 380,000.00 |
| Jun 30, 2021 | -93,000.00 |
| Mar 31, 2021 | 38,000.00 |
| Dec 31, 2020 | -27,000.00 |
| Sep 30, 2020 | 119,000.00 |
| Jun 30, 2020 | -71,000.00 |
| Mar 31, 2020 | -591,000.00 |
| Dec 31, 2019 | 237,000.00 |
| Sep 30, 2019 | -427,000.00 |
| Jun 30, 2019 | 200,000.00 |